BioXcel’s two most advanced clinical development programs are BXCL501, an investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine designed for the treatment of agitation and opioid withdrawal symptoms. BXCL701, an investigational, orally-administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to check point inhibitors.
BXCL501 is an investigational, proprietary, orally dissolving, thin film formulation of dexmedetomidine, a selective alpha-2a receptor agonist for the treatment of agitation and opioid withdrawal symptoms.
BXCL501 is our most advanced neuroscience clinical program, currently being developed for the treatment of agitation associated with schizophrenia, bipolar disorders, dementia, delirium and opioid withdrawal symptoms. As a selective adrenergic agent with a sublingual or buccal route of administration, BXCL501 is designed to be easy to administer and has demonstrated a rapid onset of action in clinical studies. BXCL501 is also designed to reduce agitation without producing excessive sedation or unarousable sleep. Managing a patient’s agitation or withdrawal symptoms represents a significant challenge for physicians and caregivers. BXCL501 has received Breakthrough Therapy designation for agitation associated with dementia and Fast Track designation for agitation associated with schizophrenia, bipolar disorders and dementia.
Based on the positive data from the SERENITY I and II pivotal trials, the Company has completed a rolling submission of its New Drug Application for the acute treatment of agitation associated with schizophrenia and bipolar disorders I and II.
In early 2021, we announced positive topline results from the TRANQUILITY Phase 1b/2 trial for the acute treatment of agitation associated with dementia, including Alzheimer’s disease. Following discussions with the FDA in Q2 2021, we plan on advancing BXCL501 into a late-stage clinical development program for the acute treatment of agitation associated with dementia in the second half of 2021. The Company also reported results from its RELEASE Phase 1b/2 trial for the treatment of opioid withdrawal symptoms and initiated the PLACIDITY trial, a Phase 2 trial of BXCL501 for the treatment of agitation associated with delirium, with topline data for PLACIDITY expected in Q1 2022.
BXCL701 is an investigational, orally-available systemic innate immunity activator with dual mechanisms of action. Designed to bridge the innate and adaptive immune systems, BXCL701 has the potential to inhibit dipeptidyl peptidase (DPP) 8/9 and block immune evasion by targeting Fibroblast Activation Protein (FAP). BXCL701 is currently being developed for the treatment of aggressive forms of prostate cancer and advanced solid ‘hot’ tumors that are refractory or treatment naïve to checkpoint inhibitors.
BXCL701 currently has two ongoing combination therapy clinical trials: The Company is currently conducting a Phase 1b/2 trial of BXCL701 in combination with KEYTRUDA® (pembrolizumab) for castrate resistant prostate cancer (CRPC), including the aggressive variant t-NEPC. The Phase 1b safety assessment of BXCL701 indicated that a split dose totaling 0.6 mg per day is the recommended Phase 2 dose when used in combination with KEYTRUDA. BioXcel has entered into the Phase 2 efficacy portion of this trial, with efficacy data expected in mid-2021.
The MD Anderson-led Phase 2 open-label basket trial was designed to evaluate the response rate of orally-administered BXCL701, combined with KEYTRUDA, in two arms: Arm A is enrolling checkpoint naïve patients where checkpoint therapy is indicated (also referred to as “hot tumors”); and Arm B is enrolling patients who have progressed following checkpoint therapy alone. The Stage 1 efficacy bar was met for both arms, allowing the trial to advance to completion. The Company plans to report efficacy data in mid-2021.